TB-500 5mg
Synthetic fragment of thymosin beta-4 investigated in preclinical models for actin regulation, angiogenesis, and tissue regeneration.
Mechanism
Thymosin beta-4 fragment studied for actin binding, angiogenesis and tissue repair in preclinical models.
Dosing
250–500 mcg once daily for 4–6 weeks, then a maintenance phase.
Reconstitution
Add 2.0 mL bacteriostatic water to yield a final concentration of 2.5 mg/mL.
Storage
Lyophilized: −20 °C; reconstituted: refrigerate 2–8 °C.
Mix & measure TB-500 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure TB-500 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 20.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Loading Phase (Weeks 1–4) | 250 mcg once daily | 10 units (0.10 mL) |
| Escalated Phase (Weeks 5–6) | 500 mcg once daily | 20 units (0.20 mL) |
| Maintenance Phase (Ongoing) | 250 mcg twice weekly | 10 units (0.10 mL) |
Reconstitution Steps
- 1
Remove the 5 mg lyophilized TB-500 vial from −20 °C storage and allow it to equilibrate to room temperature for approximately 15 minutes.
- 2
Swab the rubber stopper of both the peptide vial and the bacteriostatic water vial with a sterile alcohol swab and allow them to air-dry completely.
- 3
Using a sterile syringe, precisely draw 2.0 mL of bacteriostatic water.
- 4
Insert the syringe needle at an angle into the peptide vial and slowly inject the bacteriostatic water down the inner glass wall to prevent shearing the peptide.
- 5
Gently roll or swirl the vial until the lyophilized cake is fully dissolved into a clear solution without shaking vigorously.
- 6
Label the vial with the reconstitution date, final concentration (2.5 mg/mL), and immediately place it into refrigerated storage between 2–8 °C.
Supplies Needed
Peptide Vial
Contains 5 mg of lyophilized TB-500 active peptide, sufficient for 10 to 20 doses depending on the experimental protocol.
Insulin Syringes (U-100)
Calibrated 100-unit syringes used to measure precise micro-volume doses, requiring 1 syringe per administration event.
Bacteriostatic Water
Provides sterile diluent preserved with 0.9% benzyl alcohol, requiring 2.0 mL for full vial reconstitution.
Alcohol Swabs
Sterile 70% isopropyl alcohol wipes for aseptic preparation of vial septa before every needle puncture.
Why researchers study it
Tissue & wound repair
Mobility & flexibility
Angiogenesis
Recovery research
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
TB-500 is a synthetic peptide derived from the active actin-binding domain of the naturally occurring 43-amino-acid peptide thymosin beta-4. Structurally, it commonly corresponds to the short peptide motif Ac-LKKTETQ, which represents residues 17 through 23 of the parent protein. This specific domain is identified as the minimal sequence required to sequester monomeric globular actin, a biological function central to dynamic cellular cytoskeleton remodeling and cell mobility. In preclinical research models, TB-500 is evaluated for its downstream actions in cell migration, microvascular tube formation, and extracellular matrix remodeling. By modulating free actin dynamics, it promotes the directional movement of keratinocytes, fibroblasts, and endothelial cells toward target sites of injury. Investigations also examine its secondary signaling roles in downregulating focal inflammatory responses and upregulating local vascular endothelial factors in soft tissues. While full-length thymosin beta-4 has entered clinical development across multiple tissue injury indications, TB-500 remains strictly a preclinical research compound. It is frequently applied in animal models and cell culture frameworks assessing tendon repair, dermal wound healing, and musculoskeletal rehabilitation to elucidate fragment-specific bioactivity and therapeutic potential.
References
- 1.Philp et al., The FASEB Journal, 2003 — Identification of the central actin-binding sequence LKKTETQ as essential for angiogenic and migratory properties of thymosin beta-4
- 2.Goldstein et al., Expert Opinion on Biological Therapy, 2012 — Structure, multi-functional cellular biology, and clinical evaluation of thymosin beta-4 in wound and tissue repair
- 3.McGuire et al., Applied Sciences, 2026 — Scoping review on thymosin beta-4 and TB-500 literature across musculoskeletal repair, wound healing, and regeneration models
- 4.Xue et al., Structure, 2014 — Structural basis and mechanisms of actin-monomer sequestration by beta-thymosins
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allIpamorelin + Tesamorelin 10mg Blend (5+5 mg)
A dual-action 1:1 GH secretagogue blend pairing a stabilized GHRH analog with a selective ghrelin receptor agonist for experimental research.
View ProtocolB7-33 10mg
A synthetic single-chain relaxin-2 mimetic engineered to selectively activate RXFP1 signaling for preclinical anti-fibrotic research.
View ProtocolMelanotan II 10mg
Synthetic melanocortin receptor agonist evaluated in preclinical models for skin pigmentation, libido stimulation, and appetite modulation.
View Protocol